Edition:
India

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

243.86USD
28 Apr 2017
Change (% chg)

$0.81 (+0.33%)
Prev Close
$243.05
Open
$243.09
Day's High
$244.15
Day's Low
$241.74
Volume
463,995
Avg. Vol
832,021
52-wk High
$261.27
52-wk Low
$184.58

AGN.N

Chart for AGN.N

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.15
Market Cap(Mil.): $80,351.37
Shares Outstanding(Mil.): 335.50
Dividend: 0.70
Yield (%): 1.17

Financials

  AGN.N Industry Sector
P/E (TTM): -- 29.41 30.38
EPS (TTM): -3.12 -- --
ROI: -0.75 13.85 13.36
ROE: -1.71 14.79 14.50

BRIEF-Allergan completes Zeltiq acquisition

* Allergan successfully completes zeltiq® aesthetics acquisition Source text for Eikon: Further company coverage:

28 Apr 2017

CCI orders antitrust probe into Roche cancer drug

MUMBAI India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.

27 Apr 2017

India watchdog orders antitrust probe into Roche cancer drug

MUMBAI India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.

27 Apr 2017

UPDATE 1-India watchdog orders antitrust probe into Roche cancer drug

MUMBAI, April 27 India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.

27 Apr 2017

BRIEF-Paratek Pharma, Zai Lab announce agreement

* Paratek Pharmaceuticals and Zai Lab announce collaboration, development and license agreement for omadacycline in China

24 Apr 2017

Allergan, Argentum settle patent dispute over eye drug Restasis

U.S. generic drug company Argentum Pharmaceuticals LLC said on Tuesday it had reached an agreement with Allergan Plc that settles a patent dispute over the generic version of Allergan's eye drug, Restasis.

19 Apr 2017

Allergan, Argentum settle patent dispute over eye drug Restasis

April 18 U.S. generic drug company Argentum Pharmaceuticals LLC said on Tuesday it had reached an agreement with Allergan Plc that settles a patent dispute over the generic version of Allergan's eye drug, Restasis.

19 Apr 2017

BRIEF-Argentum Pharmaceuticals, Allergan settle patent dispute over Restasis

* Argentum PHARMACEUTICALS and Allergan settle patent dispute over Restasis

19 Apr 2017

BRIEF-Novartis expands trials for NASH via collaboration with Allergan

* Novartis expands development programs for NASH through clinical collaboration with Allergan

18 Apr 2017

BRIEF-Allergan says it has entered into a clinical trial agreement with Novartis to conduct a phase 2b study

* Announced it has entered into a clinical trial agreement with Novartis to conduct a phase 2b study, using Allergan's Cenicriviroc

18 Apr 2017

More From Around the Web

Earnings vs. Estimates